Acura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million

Reuters

Sep 04, 2025

Acura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million

Acura Pharmaceuticals Inc. has announced an amendment to their existing loan agreement with Abuse Deterrent Pharma, LLC, as detailed in a recent Form 8-K filing. The amended loan schedule, dated November 10, 2022, outlines a series of additional loans, with the aggregate principal amount now reaching $8,694,279. This update includes new loans numbered 27 through 43, spanning from January 2025 to September 2025, each with varying amounts. The amendment reflects Acura Pharmaceuticals' continued efforts to secure necessary funding for its operations. The agreement was signed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals, on September 3, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087312), on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564374128"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564374128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564374128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564374128","market":"nz","top_or_hot":-1,"title":"Acura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acura Pharmaceuticals Inc. has announced an amendment to their existing loan agreement with Abuse Deterrent Pharma, LLC, as detailed in a recent Form 8-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> filing. The amended loan schedule, dated November 10, 2022, outlines a series of additional loans, with the aggregate principal amount now reaching $8,694,279. This update includes new loans numbered 27 through 43, spanning from January 2025 to September 2025, each with varying amounts. The amendment reflects Acura Pharmaceuticals' continued efforts to secure necessary funding for its operations. The agreement was signed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals, on September 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087312), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acura Pharmaceuticals Inc. has announced an amendment to their existing loan agreement with Abuse Deterrent Pharma, LLC, as detailed in a recent Form 8-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> filing. The amended loan schedule, dated November 10, 2022, outlines a series of additional loans, with the aggregate principal amount now reaching $8,694,279. This update includes new loans numbered 27 through 43, spanning from January 2025 to September 2025, each with varying amounts. The amendment reflects Acura Pharmaceuticals' continued efforts to secure necessary funding for its operations. The agreement was signed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals, on September 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087312), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL81GxKp:1","article_id":"2564374128","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564374128","pubTimestamp":1756988608,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million. Acura Pharmaceuticals Inc. has announced an amendment to their existing loan agreement with Abuse Deterrent Pharma, LLC, as detailed in a recent Form 8-K filing. The amended loan schedule, dated November 10, 2022, outlines a series of additional loans, with the aggregate principal amount now reaching $8,694,279. This update includes new loans numbered 27 through 43, spanning from January 2025 to September 2025, each with varying amounts. The amendment reflects Acura Pharmaceuticals' continued efforts to secure necessary funding for its operations. The agreement was signed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals, on September 3, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ACUR":"阿库拉制药"},"translate_title":"Acura Pharmaceuticals Inc.修订了与Abuse Deterrent Pharma，LLC的担保本票，将贷款增加到超过800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACUR":0.9},"content_text":"Acura Pharmaceuticals Inc. Amends Secured Promissory Note with Abuse Deterrent Pharma, LLC, Increasing Loan to Over $8 Million\n    \n\n        Acura Pharmaceuticals Inc. has announced an amendment to their existing loan agreement with Abuse Deterrent Pharma, LLC, as detailed in a recent Form 8-K filing. The amended loan schedule, dated November 10, 2022, outlines a series of additional loans, with the aggregate principal amount now reaching $8,694,279. This update includes new loans numbered 27 through 43, spanning from January 2025 to September 2025, each with varying amounts. The amendment reflects Acura Pharmaceuticals' continued efforts to secure necessary funding for its operations. The agreement was signed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals, on September 3, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087312), on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}